PubRank

Peter Vandenberghe

Author PubWeight™ 125.24‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005 17.41
2 A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003 11.17
3 Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009 8.03
4 Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010 4.90
5 Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 2007 3.48
6 Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012 2.78
7 Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet 2012 2.64
8 Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma 2008 2.12
9 A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet 2011 1.99
10 Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2005 1.99
11 In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica 2008 1.69
12 Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet 2010 1.68
13 External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 2011 1.59
14 ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 2003 1.47
15 Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 2010 1.46
16 Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia? Leuk Res 2012 1.44
17 Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003 1.40
18 [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003 1.35
19 Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. J Clin Oncol 2012 1.28
20 Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood 2005 1.27
21 Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell 2011 1.27
22 Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes Chromosomes Cancer 2007 1.27
23 Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008 1.24
24 Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008 1.16
25 Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol 2012 1.15
26 ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica 2010 1.14
27 Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006 1.10
28 The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). Haematologica 2011 1.10
29 JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood 2011 1.09
30 High accuracy mutation detection in leukemia on a selected panel of cancer genes. PLoS One 2012 1.08
31 A male with angioimmunoblastic T-cell lymphoma and proliferative glomerulonephritis. Ann Hematol 2004 1.06
32 A large kindred with X-linked neutropenia with an I294T mutation of the Wiskott-Aldrich syndrome gene. Br J Haematol 2008 1.03
33 Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood 2012 1.01
34 G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. Haematologica 2009 0.99
35 Blockade of CTLA-4 enhances allergic sensitization and eosinophilic airway inflammation in genetically predisposed mice. Eur J Immunol 2002 0.99
36 EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22. Haematologica 2008 0.98
37 Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res 2010 0.98
38 The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation. Haematologica 2009 0.96
39 Hepatosplenic gammadelta T-cell lymphoma after liver transplantation: report of the first 2 cases and review of the literature. Liver Transpl 2009 0.95
40 Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma? Leuk Lymphoma 2007 0.94
41 PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood 2011 0.94
42 Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 2007 0.93
43 Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood 2014 0.93
44 Hodgkin lymphoma: Response assessment by revised International Workshop Criteria. Leuk Lymphoma 2007 0.90
45 A flow cytometric method for determination of absolute counts of myeloid precursor dendritic cells in peripheral blood. J Immunol Methods 2004 0.89
46 Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: A Belgian multicentric study. Genes Chromosomes Cancer 2009 0.89
47 Case of megaloblastic anemia caused by intestinal taeniasis. Ann Hematol 2004 0.89
48 ICON: Eosinophil Disorders. World Allergy Organ J 2012 0.88
49 Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma. Am J Pathol 2002 0.87
50 Activating WASP mutations associated with X-linked neutropenia result in enhanced actin polymerization, altered cytoskeletal responses, and genomic instability in lymphocytes. J Exp Med 2010 0.87
51 Telomeric IGH losses detectable by fluorescence in situ hybridization in chronic lymphocytic leukemia reflect somatic VH recombination events. J Mol Diagn 2007 0.87
52 Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. Ann Hematol 2011 0.86
53 Chromosomal translocations involving the IGH@ locus in B-cell precursor acute lymphoblastic leukemia: 29 new cases and a review of the literature. Cancer Genet 2013 0.84
54 An inv(16)(p13q22) positive acute myeloid leukaemia relapsing as acute precursor B-cell lymphoblastic leukaemia. Haematologica 2004 0.84
55 Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformation. Blood 2011 0.84
56 Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood 2012 0.82
57 Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma. Int J Cancer 2013 0.82
58 Interphase fluorescence in situ hybridization on selected plasma cells is superior in the detection of cytogenetic aberrations in plasma cell dyscrasia. Genes Chromosomes Cancer 2010 0.81
59 t(X;14)(p11.4;q32.33) is recurrent in marginal zone lymphoma and up-regulates GPR34. Haematologica 2011 0.80
60 Effect of corticosteroids on 18F-FDG uptake in tumor lesions after chemotherapy. J Nucl Med 2007 0.80
61 The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: a single centre study of 131 patients. Leuk Res 2007 0.79
62 Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis. Cancer Genet Cytogenet 2007 0.79
63 Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma 2007 0.79
64 Suitability of small bronchoscopic tumour specimens for lung cancer genotyping. Respiration 2014 0.79
65 t(3;11)(q12;p15)/NUP98-LOC348801 fusion transcript in acute myeloid leukemia. Haematologica 2008 0.79
66 EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells. Br J Haematol 2011 0.79
67 Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy. Leuk Res 2009 0.78
68 Rearrangement of NOTCH1 or BCL3 can independently trigger progression of CLL. Blood 2012 0.78
69 Leukemic recombinations involving heterochromatin in myeloproliferative disorders with t(1;9). Cancer Genet Cytogenet 2005 0.78
70 Amplification of the G allele at SNP rs6983267 in 8q24 amplicons in myeloid malignancies as cause of the lack of MYC overexpression? Blood Cells Mol Dis 2011 0.78
71 Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation. J Heart Lung Transplant 2002 0.78
72 Recipient-derived chronic lymphocytic leukaemia diagnosed shortly after kidney transplantation on protocol biopsy. Nephrol Dial Transplant 2009 0.78
73 BMI1, the polycomb-group gene, is recurrently targeted by genomic rearrangements in progressive B-cell leukemia/lymphoma. Genes Chromosomes Cancer 2013 0.78
74 HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP 3receptor / Bcl-2 complexes. Int J Dev Biol 2015 0.77
75 Methylation analysis of the imprinted DLK1-GTL2 domain supports the random parental origin of the IGH-involving del(14q) in B-cell malignancies. Epigenetics 2009 0.77
76 Immature and mature monocyte-derived dendritic cells in myelodysplastic syndromes of subtypes refractory anemia or refractory anemia with ringed sideroblasts display an altered cytokine profile. Leuk Res 2006 0.76
77 Fusion of ETV6 to GOT1 in a case with myelodysplastic syndrome and t(10;12)(q24;p13). Haematologica 2006 0.76
78 PDS5A, a novel translocation partner of MLL in acute myeloid leukemia. Leuk Res 2012 0.76
79 FOXP1 and PAX5 are rare but recurrent translocations partners in acute lymphoblastic leukemia. Cancer Genet 2011 0.76
80 Patients with myelodysplastic syndrome and two clones with different interstitial deletions of the long arm of chromosome 5. Leuk Lymphoma 2013 0.75
81 Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1. Br J Haematol 2014 0.75
82 New flow cytometry in hematologic malignancies. Haematologica 2009 0.75
83 Targeted Therapy with Rituximab in Felty's Syndrome: A Case Report. Open Rheumatol J 2012 0.75
84 The different faces of Janus kinase inhibition. Haematologica 2012 0.75
85 Translocation t(1;11)(q21;q23): a new finding in congenital acute myeloid leukemia. Leuk Lymphoma 2013 0.75
86 The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcome. Br J Haematol 2010 0.75
87 Aplastic anemia after transplantation for non-A, non-B, non-C fulminant hepatic failure: case report and review of the literature. Transpl Int 2002 0.75
88 CML with e6a2 BCR-ABL1 transcript: an aggressive entity? Ann Hematol 2011 0.75
89 Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE. Melanoma Res 2017 0.75
90 Recurrent breakpoints in 14q32.13/TCL1A region in mature B-cell neoplasms with villous lymphocytes. Leuk Lymphoma 2012 0.75